Servier and MiNA Therapeutics Collaborate to Develop saRNA Therapies for Neurological Diseases

 Servier and MiNA Therapeutics Collaborate to Develop saRNA Therapies for Neurological Diseases

Servier and MiNA Therapeutics Collaborate to Develop saRNA Therapies for Neurological Diseases

Shots:

  • MiNA to receive $267.6M in up front, exclusivity fee on first neurological target and will be eligible to receive research, development, regulatory and commercial milestones along with royalties
  • Servier will lead pre/ clinical development of lead candidates and will have the rights to commercialize any products that emerges from the collaboration
  • The collaboration integrates Servier’s CNS expertise and MiNA’s small activating RNA technology to identify new potential treatments for restoring normal cell function in neurological disorders

Click here ­to­ read full press release/ article | Ref: Businesswire| Image: Nohat

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post